treating
Disease Networks
Developing Therapies that Comprehensively Target Cell Networks and Tumor Micro-Environments
Oncology
TTX Founder Michael B. Sporn, MD spent over three decades at the National Cancer Institute building a career committed to both treating and preventing cancer. TTX compounds were originally intended to treat cancers and are specifically designed with the knowledge that inflammation and oxidative stress are unique and important drivers of carcinogenesis. Our pipeline of compounds has broad potential to treat multiple cancers.
Other Chronic Diseases
Inflammation and oxidative stress are not only confined to cancers. They play a key role in the causation of many other chronic diseases throughout the body. Because of their ability to achieve high concentrations in many organs, including penetration of the blood-brain barrier, TTX drugs offer promising treatment for major neurodegenerative diseases such as Parkinson’s, Alzheimer’s, multiple sclerosis, and amyotrophic lateral sclerosis (ALS).